Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis

What is the purpose of this trial?

Cystic Fibrosis (CF) is a fatal, recessive genetic disorder characterized by progressive inflammation and lung damage. It is unclear whether current treatment strategies, which focus on detection and eradication of pathogenic microorganisms in the lung, are the best way to prevent the initiation of early inflammation and lung damage. This study asks how early acquisition of microbial flora occurs in infants with CF and healthy baby controls, and whether this process initiates or influences early inflammation and clinical disease progression in CF.

Participation Guidelines

Ages: 3 months - 4 years

Gender: Both

National Heart, Lung, and Blood Institute

Start Date: 07/20/2012

End Date: 08/01/2019

Last Updated: 02/22/2018

Study HIC#: 1206010476

Get Involved

For more information about this study, contact:
Catalina Guzman
+1 203-836-7172

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Marie Egan

Principal Investigator